358 related articles for article (PubMed ID: 34625831)
21. Practical Measures of Clinical Benefit With Ruxolitinib Therapy: An Exploratory Analysis of COMFORT-I.
Miller CB; Komrokji RS; Mesa RA; Sun W; Montgomery M; Verstovsek S
Clin Lymphoma Myeloma Leuk; 2017 Aug; 17(8):479-487. PubMed ID: 28606598
[TBL] [Abstract][Full Text] [Related]
22. Definition and management of ruxolitinib treatment failure in myelofibrosis.
Pardanani A; Tefferi A
Blood Cancer J; 2014 Dec; 4(12):e268. PubMed ID: 25501025
[TBL] [Abstract][Full Text] [Related]
23. Efficacy and safety of ruxolitinib in patients with myelofibrosis: a retrospective and multicenter experience in Turkey.
Soyer N; Ali R; Turgut M; Haznedaroğlu İC; Yılmaz F; Aydoğdu İ; Pir A; Karakuş V; Özgür G; Kiş C; Ceran F; İlhan G; Özkan M; Aslaner M; İnce İ; Yavaşoğlu İ; Gediz F; Sönmez M; Güvenç B; Özet G; Kaya E; Vural F; Şahin F; Töbü M; Durusoy R; Saydam G
Turk J Med Sci; 2021 Jun; 51(3):1033-1042. PubMed ID: 33315343
[TBL] [Abstract][Full Text] [Related]
24. Risk factors for progression to blast phase and outcome in 589 patients with myelofibrosis treated with ruxolitinib: Real-world data.
Palandri F; Breccia M; Tiribelli M; Bonifacio M; Benevolo G; Iurlo A; Elli EM; Binotto G; Tieghi A; Polverelli N; Martino B; Abruzzese E; Bergamaschi M; Heidel FH; Cavazzini F; Crugnola M; Bosi C; Isidori A; Auteri G; Forte D; Latagliata R; Griguolo D; Cattaneo D; Trawinska M; Bartoletti D; Krampera M; Semenzato G; Lemoli RM; Cuneo A; Di Raimondo F; Vianelli N; Cavo M; Palumbo GA
Hematol Oncol; 2020 Aug; 38(3):372-380. PubMed ID: 32271957
[TBL] [Abstract][Full Text] [Related]
25. Momelotinib versus best available therapy in patients with myelofibrosis previously treated with ruxolitinib (SIMPLIFY 2): a randomised, open-label, phase 3 trial.
Harrison CN; Vannucchi AM; Platzbecker U; Cervantes F; Gupta V; Lavie D; Passamonti F; Winton EF; Dong H; Kawashima J; Maltzman JD; Kiladjian JJ; Verstovsek S
Lancet Haematol; 2018 Feb; 5(2):e73-e81. PubMed ID: 29275119
[TBL] [Abstract][Full Text] [Related]
26. Ruxolitinib: the first agent approved for myelofibrosis.
Verstovsek S
Clin Adv Hematol Oncol; 2012 Feb; 10(2):111-3. PubMed ID: 22402352
[No Abstract] [Full Text] [Related]
27. A phase Ib study to assess the efficacy and safety of vismodegib in combination with ruxolitinib in patients with intermediate- or high-risk myelofibrosis.
Couban S; Benevolo G; Donnellan W; Cultrera J; Koschmieder S; Verstovsek S; Hooper G; Hertig C; Tandon M; Dimier N; Malhi V; Passamonti F
J Hematol Oncol; 2018 Sep; 11(1):122. PubMed ID: 30249277
[TBL] [Abstract][Full Text] [Related]
28. Ruxolitinib for myelofibrosis in elderly non-transplant patients: healthcare resource utilization and costs.
Gerds AT; Yu J; Shah A; Xi A; Kumar S; Scherber R; Parasuraman S
J Med Econ; 2023; 26(1):843-849. PubMed ID: 37294103
[TBL] [Abstract][Full Text] [Related]
29. [Ruxolitinib prescription in myelofibrosis].
Lemal R; Robin M; Ravinet A; Cacheux V; Guièze R; Bay JO
Bull Cancer; 2013 Sep; 100(9):897-902. PubMed ID: 23985569
[TBL] [Abstract][Full Text] [Related]
30. A multinational, open-label, phase 2 study of ruxolitinib in Asian patients with myelofibrosis: Japanese subset analysis.
Oritani K; Okamoto S; Tauchi T; Saito S; Ohishi K; Handa H; Takenaka K; Gopalakrishna P; Amagasaki T; Ito K; Akashi K
Int J Hematol; 2015 Mar; 101(3):295-304. PubMed ID: 25638222
[TBL] [Abstract][Full Text] [Related]
31. Efficacy, safety, and survival with ruxolitinib in patients with myelofibrosis: results of a median 3-year follow-up of COMFORT-I.
Verstovsek S; Mesa RA; Gotlib J; Levy RS; Gupta V; DiPersio JF; Catalano JV; Deininger MW; Miller CB; Silver RT; Talpaz M; Winton EF; Harvey JH; Arcasoy MO; Hexner EO; Lyons RM; Raza A; Vaddi K; Sun W; Peng W; Sandor V; Kantarjian H;
Haematologica; 2015 Apr; 100(4):479-88. PubMed ID: 25616577
[TBL] [Abstract][Full Text] [Related]
32. Janus activated kinase inhibition in myelofibrosis.
Malhotra H
Indian J Cancer; 2012; 49(3):260-5. PubMed ID: 23238141
[TBL] [Abstract][Full Text] [Related]
33. Impact of mutational status on outcomes in myelofibrosis patients treated with ruxolitinib in the COMFORT-II study.
Guglielmelli P; Biamonte F; Rotunno G; Artusi V; Artuso L; Bernardis I; Tenedini E; Pieri L; Paoli C; Mannarelli C; Fjerza R; Rumi E; Stalbovskaya V; Squires M; Cazzola M; Manfredini R; Harrison C; Tagliafico E; Vannucchi AM; ;
Blood; 2014 Apr; 123(14):2157-60. PubMed ID: 24458439
[TBL] [Abstract][Full Text] [Related]
34. Real-world clinical outcomes of patients with myelofibrosis treated with ruxolitinib: a medical record review.
Passamonti F; Heidel FH; Parikh RC; Ajmera M; Tang D; Nadal JA; Davis KL; Abraham P
Future Oncol; 2022 Jun; 18(18):2217-2231. PubMed ID: 35388710
[No Abstract] [Full Text] [Related]
35. Patient characteristics and outcomes after ruxolitinib discontinuation in patients with myelofibrosis.
Mascarenhas J; Mehra M; He J; Potluri R; Loefgren C
J Med Econ; 2020 Jul; 23(7):721-727. PubMed ID: 32159402
[No Abstract] [Full Text] [Related]
36. Phase III MANIFEST-2: pelabresib + ruxolitinib vs placebo + ruxolitinib in JAK inhibitor treatment-naive myelofibrosis.
Harrison CN; Gupta VK; Gerds AT; Rampal R; Verstovsek S; Talpaz M; Kiladjian JJ; Mesa R; Kuykendall AT; Vannucchi AM; Palandri F; Grosicki S; Devos T; Jourdan E; Wondergem MJ; Al-Ali HK; Buxhofer-Ausch V; Alvarez-Larrán A; Patriarca A; Kremyanskaya M; Mead AJ; Akhani S; Sheikine Y; Colak G; Mascarenhas J
Future Oncol; 2022 Sep; 18(27):2987-2997. PubMed ID: 35950489
[TBL] [Abstract][Full Text] [Related]
37. Health-related quality of life and symptoms in patients with myelofibrosis treated with ruxolitinib versus best available therapy.
Harrison CN; Mesa RA; Kiladjian JJ; Al-Ali HK; Gisslinger H; Knoops L; Squier M; Sirulnik A; Mendelson E; Zhou X; Copley-Merriman C; Hunter DS; Levy RS; Cervantes F; Passamonti F; Barbui T; Barosi G; Vannucchi AM
Br J Haematol; 2013 Jul; 162(2):229-39. PubMed ID: 23672349
[TBL] [Abstract][Full Text] [Related]
38. Long-term effects of ruxolitinib versus best available therapy on bone marrow fibrosis in patients with myelofibrosis.
Kvasnicka HM; Thiele J; Bueso-Ramos CE; Sun W; Cortes J; Kantarjian HM; Verstovsek S
J Hematol Oncol; 2018 Mar; 11(1):42. PubMed ID: 29544547
[TBL] [Abstract][Full Text] [Related]
39. JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis.
Harrison C; Kiladjian JJ; Al-Ali HK; Gisslinger H; Waltzman R; Stalbovskaya V; McQuitty M; Hunter DS; Levy R; Knoops L; Cervantes F; Vannucchi AM; Barbui T; Barosi G
N Engl J Med; 2012 Mar; 366(9):787-98. PubMed ID: 22375970
[TBL] [Abstract][Full Text] [Related]
40. Impact of ruxolitinib on the natural history of primary myelofibrosis: a comparison of the DIPSS and the COMFORT-2 cohorts.
Passamonti F; Maffioli M; Cervantes F; Vannucchi AM; Morra E; Barbui T; Caramazza D; Pieri L; Rumi E; Gisslinger H; Knoops L; Kiladjian JJ; Mora B; Hollaender N; Pascutto C; Harrison C; Cazzola M
Blood; 2014 Mar; 123(12):1833-5. PubMed ID: 24443442
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
